Equillium Inc and Ono Pharmaceutical Co Ltd to Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab Call Transcript
Welcome and thank you for joining us this morning for Equillium's announcement regarding their exclusive option and asset purchase agreement with Ono Pharmaceuticals for the development and commercialization of itolizumab.
Presenting this morning, is Mr. Jason Keyes, Chief Financial Officer of Equillium; Mr. Bruce Steel, Chief Executive Officer of Equillium; and Dr. Stephen Connelly, Chief Scientific Officer of Equillium, will also join for Q&A following the presentation.
Before we begin, I would like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors. This include those discussed in the Risk Factors section in the company's most recent annual and quarterly reports, as well as other reports filed with the SEC. I'll remind you that this call is being recorded and a replay will be available on the company's website
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
